Compare J & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | J | WST |
|---|---|---|
| Founded | 1947 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 16.6B |
| IPO Year | 1994 | 2004 |
| Metric | J | WST |
|---|---|---|
| Price | $139.47 | $251.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $156.60 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 1.1M | 915.2K |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.04% | 0.35% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 1.12 | ★ 6.79 |
| Revenue | ★ $14,984,646,000.00 | $2,886,900,000.00 |
| Revenue This Year | $13.41 | $6.73 |
| Revenue Next Year | N/A | $6.07 |
| P/E Ratio | $124.44 | ★ $36.96 |
| Revenue Growth | ★ 49.51 | 1.95 |
| 52 Week Low | $106.23 | $187.43 |
| 52 Week High | $168.44 | $322.34 |
| Indicator | J | WST |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 52.31 |
| Support Level | $131.96 | $244.30 |
| Resistance Level | $141.60 | $261.98 |
| Average True Range (ATR) | 6.16 | 8.31 |
| MACD | 0.03 | 1.82 |
| Stochastic Oscillator | 49.32 | 72.45 |
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $12 billion in revenue in fiscal 2025.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.